Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The stock is in a well-established, long-term rising trend above the technical support level at 233.4 EUR
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 83.29 and 67.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company is not the most generous with respect to shareholders' compensation.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
SARTORIUS STEDIM BIOTECH6.46%34 549
ABBOTT LABORATORIES1.65%190 701
MEDTRONIC PLC-0.28%157 229
BECTON, DICKINSON AND COMPA..4.60%76 127
HOYA CORPORATION-2.24%50 041
ALIGN TECHNOLOGY, INC.6.15%44 726
BAXTER INTERNATIONAL INC.-0.25%40 886
DEXCOM, INC.-4.20%34 013
ZIMMER BIOMET HOLDINGS3.91%33 189
TERUMO CORPORATION-4.06%30 113
SYSMEX CORPORATION3.63%25 867
WEST PHARMACEUTICAL SERVICE..5.44%22 135
AMERISOURCEBERGEN CORPORATI..9.25%21 861
BIO-RAD LABORATORIES, INC.3.12%17 956
AVANTOR, INC.2.84%16 743
STERIS PLC-2.72%15 732
More Results
Financials
Sales 2020 1 877 M 2 266 M 2 266 M
Net income 2020 342 M 412 M 412 M
Net Debt 2020 261 M 315 M 315 M
P/E ratio 2020 83,3x
Yield 2020 0,30%
Capitalization 28 576 M 34 549 M 34 491 M
EV / Sales 2020 15,4x
EV / Sales 2021 12,7x
Nbr of Employees 6 979
Free-Float 25,7%
Upcoming event on SARTORIUS STEDIM BIOTECH
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes